Arrowhead to Rejoin the Russell Microcap Index by EON


More Info
									Arrowhead to Rejoin the Russell Microcap Index
June 14, 2010 07:03 AM Eastern Daylight Time  

PASADENA, Calif.--(EON: Enhanced Online News)--Arrowhead Research Corporation (NASDAQ:
ARWR) today announced that it will join the Russell Microcap® Index when Russell Investments reconstitutes its
family of U.S. indexes, according to a preliminary list of additions posted June 11 on The final
2010 reconstitution of the Russell Indexes will take place after the market closes on June 25, 2010 and final
membership lists will be posted on June 28 at:

"Being included in the Russell Index’s reconstitution is a validation of the progress we have made over the last year.
As we continue to execute on our growth strategy, we believe our membership will be a valuable tool to help raise
our investment profile in the financial community,” said Dr. Christopher Anzalone, Chief Executive Officer.

Russell Indexes are widely used by investment managers and institutional investors for both index funds and as
benchmarks for passive and active investment strategies. The Russell Microcap Index comprises the smallest 1,000
securities in the Russell 2000® Index, plus the next 1,000 companies, based on a ranking of all U.S. equities by
market capitalization. The Microcap Index was designed to offer managers and other investors a comprehensive,
unbiased barometer to compare their performance against the genuine microcap marketplace of stocks.

The list of preliminary additions and deletions to the Russell Indexes can be found at:

About Arrowhead Research Corporation

Arrowhead Research Corporation ( (NASDAQ: ARWR) is a nanotechnology
company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to
build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is
focused primarily on its two majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for
electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead
also has minority investments in two privately held nanobiotech companies.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and
speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and uncertainties, including the future success of our clinical
studies, our ability to successfully develop and manufacture products, rapid technological change in our industry,
changes in demand for our future products, legislative, regulatory and competitive developments and general
economic conditions. Our Annual Report on Form 10-K, and other SEC filings discuss these and other important
risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to
revise or update publicly any forward-looking statements for any reason.

The Piacente Group
Brandi Floberg, 212-481-2050


To top